140695-85-8

Basic information

• Product Name: (R)-1-Boc-3-(hyroxymethyl)piperidine
• Synonyms: (R)-tert-butyl 3-(hydroxyMethyl)piperidin-1-carboxylate;tert-butyl (3R)-3-(hydroxyMethyl)piperidine-1-carboxylate;BOC-R-PIP-3MEOH;3-(R)-N-BOC-PIPERIDINE METHANOL;N-BOC-(3R)-PIP(3-CH2OH);(R)-3-HYDROXYMETHYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-1-N-BOC-3-(HYDROXYMETHYL)PIPERIDINE;(R)-1-BOC-3-(HYDROXYMETHYL)PIPERIDINE
• CAS NO: 140695-85-8
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Product Categories: piperidine
• Mol File: 140695-85-8.mol
• Article Data: 23

Chemical Properties

• Melting Point: 77-81 °C
• Boiling Point: 308 °C at 760 mmHg
• Flash Point: 140.1 °C
• Appearance: White to yellow/Powder
• Density: 1.059 g/cm³
• Storage Temp.: 2-8°C
• PKA: 14.93±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: (R)-1-Boc-3-(hyroxymethyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-Boc-3-(hyroxymethyl)piperidine(140695-85-8)
• EPA Substance Registry System: (R)-1-Boc-3-(hyroxymethyl)piperidine(140695-85-8)

Safety Data

• Hazard Codes: Xi,N,T
• Statements: 25-36-50
• Safety Statements: 26-45-61
• RIDADR: UN2811
• Hazardous Substances Data: 140695-85-8(Hazardous Substances Data)

Usage

Uses

(R)-(-)-1-Boc-3-(hydroxymethyl)piperidine is used as pharmaceutical intermediate.

Upstream product

• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 163438-09-3 (R)-1-Boc-nipecotic acid 
• 498-95-3 (R)-nipecotic acid 
• 194726-46-0 (3R)-3-formylpiperidine-1-carboxylic acid tert-butyl ester 
• 445398-78-7 N-benzyl-hepta-4(E),6-dien-1-amine 
• 651321-53-8 Benzyl-[(E)-hepta-4,6-dien-(E)-ylidene]-amine 
• 79280-39-0 (4E)-hepta-4,6-dienal 
• 33741-15-0 methyl (4E)-hepta-4,6-dienoate 
• 140645-20-1 t-butyl (R,S)-3-<(butyryloxy)methyl>-1-piperidine-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4606-65-9 3-(hydroxymethy)piperidine 
• 108-30-5 succinic acid anhydride 
• 109-02-4 4-methyl-morpholine 
• 37675-20-0 (R)-3-hydroxymethyl piperidine 

Downstream Products

• 140645-87-0 (S)-<<(benzyloxycarbonyl)amino>methyl>piperidine-1-carboxylic acid tert-butyl ester 
• 683269-48-9 (R)-3-[(benzyloxycarbonylamino)methyl]-piperidine 
• 384830-11-9 (2S,3R)-3-((S)-1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-ylmethyl)-4-oxo-1-[4-(6-phenyl-hexanoyl)-piperazine-1-carbonyl]-azetidine-2-carboxylic acid benzyl ester 
• 384830-10-8 (2S,3R)-3-((S)-1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-ylmethyl)-4-oxo-azetidine-2-carboxylic acid benzyl ester 
• 384830-09-5 (S)-3-((2S,3R)-2-Benzyloxycarbonyl-4-oxo-azetidin-3-ylmethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 155541-67-6 (R)-3-(azidomethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 140645-24-5 tert-butyl (3S)-3-(aminomethyl)piperidine-1-carboxylate 

Relevant articles and documents

Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants

A novel class of HIV-1 protease inhibitors with flexible piperidine as the P2 ligand was designed with the aim of improving extensive interactions with the active subsites. Many inhibitors exhibited good to excellent inhibitory effect on enzymatic activity and viral infectivity. In particular, inhibitor 3a with (R)-piperidine-3-carboxamide as the P2 ligand and 4-methoxybenzenesulfonamide as the P2’ ligand showed an enzyme Ki value of 29 pM and antiviral IC50 value of 0.13 nM, more than six-fold enhancement of activity compared to DRV. Furthermore, there was no significant change in potency against DRV-resistant mutations and HIV-1NL4?3 variant for 3a. Besides, inhibitor 3a exhibited potent antiviral activity against subtype C variants with low nanomole EC50 values. In addition, the molecular modeling revealed important hydrogen bonds and other favorable van der Waals interactions with the backbone atoms of the protease and provided insight for designing and optimizing more potent HIV-1 protease inhibitors.

Palladium-catalyzed ring-closing reaction via C-N bond metathesis for rapid construction of saturated N-heterocycles

The ring-closing reactions based on chemical bond metathesis enable the efficient construction of a wide variety of cyclic systems which receive broad interest from medicinal and organic communities. However, the analogous reaction with C-N bond metathesis as a strategic fundamental step remains an unanswered challenge. Herein, we report the design of a new fundamental metallic C-N bond metathesis reaction that enables the palladium-catalyzed ring-closing reaction of aminodienes with aminals. The reactions proceed efficiently under mild conditions and exhibit broad substrate generality and functional group compatibility, leading to a wide variety of 5- to 16-membered N-heterocycles bearing diverse frameworks and functional groups.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.